DEA Boosts Amphetamine Quotas: More Meds for 2025 Without Overproduction
Published Date: 9/19/2025
Notice
Summary
The DEA is changing how much lisdexamfetamine and d-amphetamine can be made in 2025. This affects drug makers who need to follow new production limits to meet demand safely and legally. The update is happening quickly to stick to important deadlines, but it doesn’t involve any new costs for the public.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
2025 Production Limits for Two Stimulants
The DEA adjusted the 2025 aggregate production quota for the Schedule II substances lisdexamfetamine and d-amphetamine (for conversion). Drug manufacturers must follow the new 2025 production limits and the DEA expedited publication to meet the timeframes in 21 U.S.C. 826(h)(1).
No New Public Costs Announced
The DEA stated this adjustment does not involve any new costs for the public. The change is an administrative adjustment to 2025 production quotas and was published quickly to meet statutory timeframes.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in